Oncology Pharma : Financial Statements (Unaudited) for the year ended March 31, 2022

ONCOLOGY PHARMA, INC.

ANNUAL REPORT

FINANCIAL STATEMENTS

-UNAUDITED-

FOR THE YEAR ENDED

MARCH 31, 2022

Oncology Pharma, Inc.
Balance Sheets
(Unaudited)
	As of			As of
	March 31, 2022		March 31, 2021
ASSETS
CURRENT ASSETS
Cash	$	3,964	$	8,954
Total Current Assets		3,964			8,954
INVESTMENTS
Investment in NanoSmart Pharmaceuticals, Inc. Licensing Agreement		351,350			76,350
Investment in KCL Therapeutics, Inc. Licensing Agreement		1,400,000			-
Investment in Regen Biopharma, Inc. Licensing Agreement		55,000			-
Investment in Sybleu, Inc. Licensing Agreement		237,250			237,250
Investment in Kalos Therapeutics, Inc. Licensing Agreement		-			-
Investment in Ribera Solutions, LLC Licensing Agreement		75,000			25,000
Total Investments		2,118,600			338,600
FIXED ASSETS
Furniture, net		-			-
Total Fixed Assets		-			-
TOTAL ASSETS	$	2,122,564	$	347,554
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
Accounts Payable and Accrued Expenses	$	213,387	$	279,181
Loans Payable Related Party		944			885
Convertible Notes Payable Related Party		3,550			3,550
Promissory & Convertible Notes Payable		657,590			233,950
Total Current Liabilities		875,471			517,566
TOTAL LIABILITIES	$	875,471	$	517,566
STOCKHOLDERS' EQUITY ((DEFICIT)
Preferred Series A stock, $0.001 par value,		1,000			1,000
100,000,000 shares authorized, 1 share issued
and outstanding at March 31, 2022 and March 31, 2021
Common stock, $0.001 par value, 900,000,000		188,894			182,469
shares authorized, 33,763,216 and 27,338,216
issued and outstanding at March 31, 2022 and
March 31, 2021
Additional Paid In Capital		273,156,246			167,118,839
Retained Deficit		(272,099,047)			(167,472,319)
Total Stockholders' Equity (Deficit)		1,247,093			(170,012)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$	2,122,564	$	347,554
The accompanying Notes are an integral part of these financial statements

Oncology Pharma, Inc. Statements of Operation (Unaudited)

		For the Year Ended			For the Year Ended
		March 31, 2022			March 31, 2021
Revenues	$	-	$	-
Costs and Expenses					-
General and Administrative		62,049			14,410,609
Depreciation		-			779
Total Operating Expenses		62,049			14,411,388
Operating Loss		(62,049)			(14,411,388)
Other Income and Expenses
Gain from license fee settlement		54,167			-
Interest Expense		(104,618,846)			(82,809,122)
Loss from Abandonment of Mining Claims and Licenses		-			(249,121)
Total Other Income and Expenses		(104,564,679)			(83,058,243)
Net Loss Before Taxes		(104,626,728)			(97,469,631)
Income Taxes		-			(3,494)
Net Loss	$	(104,626,728)		$	(97,473,125)
Net Loss Per Common Share (Basic and Diluted)	$	(3.42)	$	(6.76)
Weighted Average Common Shares Outstanding (Basic and Diluted)		30,550,716			14,419,839

The accompanying Notes are an integral part of these financial statements

Oncology Pharma, Inc. Statements of Cash Flow (Unaudited)

	For the Year Ended			For the Year Ended
		March 31, 2022			March 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(104,626,728)	$	(97,473,125)
Adjustments to reconcile net loss to
cash used in operating activities
Depreciation		-			779
Gain from legal settlement		(54,167)
Issuance of common stock for services					14,222,527
Issuance of common stock for interest expense		104,691,600			82,807,050
Changes in operating assets and liabilities
Accounts payable and accrued expenses		(65,795)			114,072
Loans and notes payable		423,699
Loss from abandonment of mining claims and licenses		-			211,621
NET CASH (USED) PROVIDED IN OPERATING ACTIVITIES		368,610			(117,076)
CASH FLOWS FROM INVESTING ACTIVITIES
Investment in Licensing Agreements		(1,780,000)			(321,950)
NET CASH (USED) PROVIDED FROM INVESTING ACTIVITIES		(1,780,000)			(321,950)
CASH FLOWS FROM FINANCING ACTIVITIES
Common stock to be issued for license agreements		1,400,000			34,500
Common stock issued for license agreements					274,750
Increase in related party debt					1,025
Conversion of notes payable to common stock		6,400			2,950
Stock option grant for license agreement					25,000
Issuance of Convertible Notes Payable					107,950
NET CASH PROVIDED (USED) BY FINANCING ACTIVITIES		1,406,400			446,175
NET CHANGE IN CASH		(4,990)			7,149
CASH AT BEGINNING OF PERIOD		8,954			1,805
CASH AT END OF PERIOD	$	3,964	$	8,954
SUPPLEMENTARY INFORMATION
Stock issued for debt	$	6,400	$	2,950

The accompanying Notes are an integral part of these financial statements

Oncology Pharma, Inc.

Statements of Shareholders' Equity (Deficit) (Unaudited)

Statements of Changes in Stockholder's Deficit

For the Years Ended March 31, 2022 and 2021

		Common Stock	Preferred Stock			Additional		Accumulated	Subscriptions
		Shares				Amount		Shares			Amount		Paid-in-Capital			Deficit			Receivable		Total
Balance as at March 31, 2020	1,501,461		$	150,146	1,000	$	1,000	$	69,784,384	$	(69,999,194)	$	-	$	(63,664)
Share rounding due to reverse stock split	217
Shares issued for services	20,580,038				22,066							14,200,461								14,222,527
Shares issued for licensing rights	56,500				5,007							269,743								274,750
Shares issued for debt conversion	5,200,000				5,200							82,804,800
Shares to be issued					50							34,450
Share option grant for licensing rights													25,000
Net Income (Loss) for period ending March 31, 2021																	(97,473,125)				(97,473,125)
Balance as at March 31, 2021		27,338,216		$	182,469	1,000	$	1,000	$	167,118,838	$	(167,472,319)	$	-	$	(170,012)
Balance as at March 31, 2021	27,338,216		$	182,469	1,000	$	1,000	$	167,118,838	$	(167,472,319)		-	$	(170,012)
Shares issued for licensing rights	50,000				50							1,399,950								1,400,000
Shares issued for debt conversion	6,400,000				6,400							104,691,600							104,698,000
Shares cancelled in legal settlement	(25,000)			(25)							(54,142)								(54,167)
Net Income (Loss) for period ending March 31, 2022																	(104,626,728)			(104,626,728)
Balance as at March 31, 2022		33,763,216		$	188,894	1,000	$	1,000	$	273,156,246	$	(272,099,047)		-		1,247,093

The accompanying Notes are an integral part to these financial statements.